Neurodegenerative disease

This early-stage study tests a vaccine called AV-1959D in 48 people with early Alzheimer's disease. The vaccine aims to train the immune system to target harmful amyloid plaques in the brain. The main goal is to check if the vaccine is safe and tolerable.

This phase 2a trial tests a nasal spray called foralumab in 54 people with non-active secondary progressive multiple sclerosis (SPMS). The spray contains an antibody that aims to calm overactive immune cells in the brain. Participants will receive either a low dose, a high dose, …

This study tests the long-term safety and effectiveness of an experimental drug called VX-670 in adults with myotonic dystrophy type 1 (DM1). Participants who completed a previous VX-670 study can join. The drug is given through a vein, and researchers will monitor side effects a…

This study tests a gene therapy called PBKR03 for babies with early infantile Krabbe disease, a severe genetic disorder that damages the brain and nerves. The treatment delivers a working copy of the GALC gene to the brain and body. Researchers will check safety and find the best…

This phase 2 trial tests whether allopregnanolone, a natural hormone, can safely help repair the brain in people with early Alzheimer's disease. About 100 volunteers aged 55 to 80 will receive weekly infusions of the drug or a placebo for several months. Researchers will measure …

This Phase 2 study tests an experimental drug called BIIB080 in people with mild cognitive impairment or mild dementia due to Alzheimer's disease. The drug is injected into the fluid around the spinal cord every 12 or 24 weeks. Researchers want to see if it can slow the worsening…

This early-stage trial tests a single injection of ARO-ATXN2 in 36 adults with spinocerebellar ataxia type 2, a rare genetic disorder that affects movement and coordination. The main goal is to see if the drug is safe and how the body processes it. Participants are randomly assig…

This study tests an experimental drug called ONO-2808 in people with multiple system atrophy (MSA), a rare and serious brain disease. About 92 participants will receive either the drug or a placebo daily for up to 80 weeks. The goal is to see if the drug is safe and might help co…

This phase 2 trial tests whether the experimental drug VHB937 can slow the decline in function and delay the need for breathing support in people with early-stage ALS. About 251 participants will receive either VHB937 or a placebo for 40 weeks, followed by an open-label extension…

This early-stage trial tests an experimental drug called BI 3000202 in 16 adults with rare type 1 interferonopathies, such as Aicardi-Goutières syndrome. Participants take a low dose for 4 weeks, then a higher dose for 36 weeks. The main goal is to see if the drug is safe and how…

This study planned to test whether injecting botulinum toxin (Botox) into the salivary glands could reduce drooling in people with true bulbar palsy, a condition that causes swallowing problems after a brain stem injury. The trial was designed to compare the injections against st…

This phase 2 trial tests whether adding a second DNA vaccine to a standard immunotherapy (pembrolizumab) can improve outcomes for men with castration-resistant metastatic prostate cancer. About 60 participants will receive either one or two DNA vaccines along with pembrolizumab f…

This study aimed to test a new treatment called CABA-201, a CAR T-cell therapy made from a patient's own immune cells, for people with multiple sclerosis (MS). The goal was to see if it was safe and could control the disease by targeting and resetting the immune system. However, …

This Phase 3 study compares fenebrutinib, an experimental oral drug, to teriflunomide, an approved MS therapy, in 751 adults with relapsing multiple sclerosis. The goal is to see if fenebrutinib better reduces relapse rates and delays disability progression. Participants take eit…

This phase 3 trial tests whether the drug troriluzole can slow the progression of spinocerebellar ataxia, a rare genetic disorder that affects coordination and balance. About 300 adults with different types of SCA are randomly assigned to take either troriluzole or a placebo dail…

This phase 3 trial compares two drugs for primary progressive multiple sclerosis (PPMS), a form of MS that steadily worsens. About 985 adults with PPMS will receive either daily oral fenebrutinib or intravenous ocrelizumab (plus matching placebos) to see which better delays disab…

This study planned to test a new CAR-T cell therapy called LCAR-AIO in adults with relapsed or treatment-resistant neurological autoimmune diseases, including multiple sclerosis and myasthenia gravis. The goal was to check safety and find the right dose. However, the trial was wi…

This Phase 3 trial tests whether the oral drug remibrutinib works better than teriflunomide at reducing relapses and slowing disability in people with relapsing multiple sclerosis. About 1,000 adults aged 18–55 with active MS are taking part. The study is double-blind, meaning ne…

This study tests an investigational drug called rozanolixizumab in adults with MOG antibody-associated disease (MOGAD), a rare condition where the immune system attacks the brain and spinal cord. The main goal is to see if the drug can prevent or delay relapses (flare-ups) compar…

This early-stage trial tests whether a single infusion of donated mesenchymal stem cells is safe for children with cerebral adrenoleukodystrophy (cALD), a rare and life-threatening brain disease. The stem cells are given as a temporary bridge to buy time before a more definitive …

This study tests a donor stem cell transplant for people with severe immune system problems, like SCID and Wiskott-Aldrich syndrome. The goal is to help the body make healthy blood cells and fight infections. Participants receive donated stem cells to rebuild their immune system.…

This phase 3 trial tests whether a shot (subcutaneous) of ublituximab works as well as the standard IV infusion for people with relapsing multiple sclerosis. About 360 participants are enrolled. The main goal is to compare drug levels in the blood over 24 weeks, along with safety…

This study looks at whether a one-year treatment with Ocrevus can improve walking and balance in people with relapsing multiple sclerosis, compared to other standard treatments. Sixty adults aged 18-65 who can walk at least 25 feet will be split into two groups. Their walking abi…

This study is a long-term follow-up for people with relapsing multiple sclerosis who previously completed a ublituximab trial. It aims to see if the drug remains safe and effective over time. About 1100 participants will receive ublituximab infusions, and researchers will track r…

This study tests different dosing schedules of the drug donanemab in about 1,175 people with early symptomatic Alzheimer's disease. The goal is to find a regimen that lowers brain amyloid plaques while reducing the risk of a side effect called ARIA-E (brain swelling or small blee…

This clinical trial is testing whether dimethyl fumarate, a drug already used for multiple sclerosis, can improve balance and walking in adults with adrenomyeloneuropathy (AMN), a rare nerve disease. Forty participants will take either the drug or a placebo daily for 36 months, w…

This phase 2 trial tests whether leuprolide (Eligard), a drug that lowers certain hormones, can slow memory and thinking decline in 180 women with mild Alzheimer's or mild cognitive impairment. All participants are already taking donepezil. The study compares leuprolide injection…

This early study at Mayo Clinic tests whether ultra-low, anti-inflammatory doses of radiation can slow Parkinson's disease. Twenty people with early-stage Parkinson's will receive five daily radiation treatments guided by special brain scans. The main goal is to see if the treatm…

This study tests a gene therapy called vesemnogene lantuparvovec in about 20 people with spinal muscular atrophy (SMA), a genetic condition that causes muscle weakness. The therapy delivers a working copy of the SMN1 gene to help muscles work better. The main goal is to check saf…

This study tests an experimental drug called RO7126209 (Trontinemab) in people with early to moderate Alzheimer's disease. The drug is given by IV infusion and aims to reduce amyloid plaques in the brain, a hallmark of Alzheimer's. About 241 participants will receive either the d…

This study compares the standard fixed-interval dosing of ocrelizumab (every 24 weeks) with a personalized approach where infusions are given only when B cell levels rise above a certain threshold. The goal is to see if the personalized schedule is just as good at preventing rela…

This study is a long-term extension of earlier trials testing the drug riliprubart in adults with CIDP, a condition where the immune system attacks the nerves, causing weakness and numbness. About 300 participants who completed a prior riliprubart study will continue receiving th…

This phase 3 trial tests whether rituximab, a cheaper drug, works as well as ocrelizumab for active multiple sclerosis. About 600 adults with relapsing or progressive MS will receive one of the two drugs. The main goal is to see if rituximab can prevent new brain lesions as effec…

This study tests whether adding an experimental drug (RO7204239) to an existing SMA medicine (risdiplam) can help people with spinal muscular atrophy build stronger muscles and move better. The trial includes about 259 children and young adults, ages 2 to 25, who can walk. Resear…

This early-stage trial tests a one-time gene therapy called CLN-301 in 7 children aged 3 to 10 with CLN3 Batten disease, a rare genetic disorder that causes progressive loss of vision, movement, and thinking skills. The therapy delivers a working copy of the CLN3 gene directly in…

This Phase 2 trial tests whether a patient's own stem cells, injected into the spinal fluid, can slow the progression of multiple system atrophy (MSA), a rare and fatal brain disease. The study involves 71 adults aged 30-70 with early-stage MSA. Researchers will measure changes i…

This study looks at whether the drug ofatumumab can slow down thinning of the retina (the light-sensitive layer at the back of the eye) in people with relapsing-remitting multiple sclerosis (MS). Researchers will follow 75 adults with MS who are either starting or already taking …

This study tests whether a new drug, ABP 692, works as well as the approved drug Ocrevus for people with relapsing-remitting multiple sclerosis (RRMS). About 152 adults with RRMS will receive either ABP 692 or Ocrevus to compare how the drugs move through the body and how well th…

This study tests whether the drug rapamycin is safe and tolerable for older adults with mild memory problems or early Alzheimer's disease. About 40 participants will take rapamycin for 12 months while researchers monitor side effects and changes in memory and thinking. The goal i…

This study tests whether a daily fingolimod capsule works better than a weekly interferon injection to prevent multiple sclerosis relapses in children. About 240 kids with MS will take one of the two treatments for 2 years, followed by a 5-year extension where everyone gets fingo…

This phase 3 trial tests whether satralizumab can prevent relapses in people with MOGAD, a rare disease where the immune system attacks the brain and spinal cord. About 152 participants aged 12 and older will receive either the drug or a placebo. The main goal is to see if satral…

This trial tests a personalized treatment plan for people with advanced colorectal cancer that has spread to the liver and stopped responding to standard treatments. The approach combines a liver-directed chemotherapy (HAIC), a targeted therapy (fruquintinib or cetuximab), and an…

This study is testing a new modular shoulder replacement system in 105 people who need complex revision surgery due to joint disease, trauma, or cancer. The device can replace part or all of the upper arm bone. Researchers are tracking how long the implant lasts and how well pati…

This study looks at whether the drug troriluzole can slow the progression of spinocerebellar ataxia (SCA), a rare genetic disease that affects movement and balance. Researchers will compare 909 patients who took troriluzole for up to three years with similar patients who did not …

This study tests an investigational drug called lecanemab in people aged 55-80 who have early signs of Alzheimer's-related brain changes but no memory problems yet. The goal is to see if the drug can slow cognitive decline and reduce amyloid buildup over about 4 years. Around 140…

This study tests whether benfotiamine, a form of vitamin B1, can safely slow memory and thinking decline in people with early Alzheimer's. About 406 adults aged 50-89 with mild symptoms will take the drug or a placebo for up to 72 weeks. Researchers will measure changes in cognit…

This Phase 3 trial tests an experimental drug called amlenetug in 401 people with multiple system atrophy (MSA), a rare and serious brain disorder. The goal is to see if the drug can slow the worsening of symptoms and improve survival. Participants receive either the drug or a pl…

This phase 2 study tests a vaccine called JNJ-64042056 in 55 people with very early signs of Alzheimer's (no symptoms yet but tau buildup in the brain). The vaccine is designed to train the immune system to attack tau protein, which forms tangles in Alzheimer's. Participants rece…

This study tests a one-time gene therapy infusion (FBX-101) given after a standard stem cell transplant in 6 children with infantile Krabbe disease, a severe genetic disorder affecting the nervous system. The therapy uses a harmless virus to deliver a working copy of the GALC gen…

This study tests an oral drug called SKY-0515 in 500 adults with Huntington's disease who have already completed a prior study of the same drug. The goal is to see if the drug can safely lower harmful proteins and improve symptoms over the long term. Participants must be 25 or ol…

This early study tests a single injection of a gene therapy called NTF001 in 12 people with ALS. The therapy aims to deliver a protein that supports nerve cell health. The main goal is to check safety, but researchers will also look for signs of benefit over 52 weeks.

This study tests whether adding taldefgrobep alfa to standard SMA treatments can improve muscle function in people with spinal muscular atrophy (SMA). About 269 participants, both walkers and non-walkers, will receive either the drug or a placebo for 48 weeks. The main goal is to…

This early-stage trial tests a drug called NIO752 in 38 people with mild Alzheimer's or mild cognitive impairment due to Alzheimer's. The drug is given as one or two injections into the spinal fluid to see if it can lower levels of tau protein, a key marker of Alzheimer's damage.…

This phase 3 study tests whether donanemab, an antibody given through an IV, can safely slow cognitive decline in 1500 people with early Alzheimer's. Participants receive either the drug or a placebo for up to 93 weeks. The main goal is to measure changes in thinking and daily fu…

This early-stage trial tests a new gene therapy called NKG001 in 21 children under 5 with spinal muscular atrophy (SMA). The therapy is given as a single dose, either through a vein or combined with a spinal injection. The main goal is to check safety and find the best dose, not …

This phase 3 trial tests whether CYB704, a proposed biosimilar to the MS drug Ocrevus, works the same way in the body. About 183 people with relapsing multiple sclerosis will receive either CYB704 or Ocrevus. Researchers will compare drug levels, MRI scans, and side effects to se…

This early-stage study tests the safety of acamprosate, a drug used for alcohol dependence, in 30 adults with ALS who have a specific mutation in the C9orf72 gene. Participants take the pill three times daily for 24 weeks and undergo regular checkups, breathing tests, and spinal …

This Phase 3 trial tests remibrutinib, an oral tablet, against teriflunomide in 1000 adults with relapsing multiple sclerosis. The goal is to see if remibrutinib better reduces yearly relapse rates and delays disability. Participants will then have the option to continue remibrut…

This study follows about 200 people with relapsing-remitting multiple sclerosis (RRMS) who are starting ozanimod (Zeposia®) for the first time. Researchers want to see how long patients continue the medication in everyday practice and how well it controls their disease. The study…

This study was designed to test whether the drug govorestat could improve symptoms of Charcot-Marie-Tooth disease caused by sorbitol dehydrogenase deficiency (CMT-SORD), a rare nerve condition. It planned to enroll people aged 16 to 65 and compare govorestat to a placebo over 36 …

This study tests a drug called ACP-204 for treating psychosis (hallucinations or delusions) in people with Lewy body dementia. It is a 52-week open-label extension, meaning all 126 participants will receive the drug. The main goal is to check for side effects over the long term. …

This study looks at whether people with relapsing-remitting MS who have not had a relapse in the past year but have high levels of a nerve damage marker (NfL) in their blood would benefit from switching to the drug ofatumumab. About 136 participants will either switch to ofatumum…

This expanded access program offers the experimental drug zervimesine (CT1812) to people aged 50 to 86 with mild-to-moderate dementia with Lewy bodies. Participants take one 100 mg pill daily for up to a year. The goal is to provide access to the drug and collect long-term safety…

This study follows about 1,900 people with relapsing multiple sclerosis who have already taken ofatumumab in a previous Novartis trial. Participants continue receiving ofatumumab injections every 4 weeks to monitor long-term safety, side effects, and how well the drug controls re…

This Phase 1 study tests the safety of OLX-07010, a drug designed to stop tau proteins from clumping in the brain—a hallmark of Alzheimer's disease. Researchers will give single or multiple doses to 88 healthy adults and elderly volunteers to see how the body handles the drug and…

This phase 2 trial tests an experimental drug called tominersen in 301 people with early-stage Huntington's disease. The drug aims to lower levels of the harmful mutant protein that causes the disease. Researchers will compare tominersen against a placebo to see if it can slow do…

This study tests a non-invasive device that uses low-frequency electromagnetic fields to improve communication between immune cells. 120 adults with lupus, rheumatoid arthritis, or multiple sclerosis will receive either active or sham sessions three times a week for 12 weeks. The…

This study tests a higher dose of nusinersen (Spinraza) in 45 teenagers and adults with spinal muscular atrophy (SMA) who cannot walk and have already taken risdiplam. Participants receive two 50 mg loading doses two weeks apart, then 28 mg every four months for about two years, …

This study tests whether adding telitacicept to standard therapy helps adults with refractory chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve condition that causes weakness and numbness. About 76 participants will receive either standard care alone or standard c…

This Phase 1 trial compares a new drug called RPH-035 to the approved MS drug Ocrevus. The study involves 180 adults with relapsing-remitting or secondary progressive multiple sclerosis who have flare-ups. Researchers are checking if RPH-035 behaves similarly in the body and has …

This early-phase trial tests an experimental drug called nL-FLVC-001 in a single person with posterior column ataxia with retinitis pigmentosa (PCARP), a rare genetic condition that causes vision loss and coordination problems. The drug is an antisense oligonucleotide injected in…

This Phase 2 trial tests fenebrutinib, an oral drug, in 109 people with relapsing multiple sclerosis. Participants receive either the drug or a placebo for 12 weeks, and researchers measure new brain lesions on MRI scans. The goal is to see if fenebrutinib can reduce disease acti…

This study compares two daily pills—fenebrutinib and teriflunomide—in about 746 adults with relapsing multiple sclerosis. The goal is to see which one better reduces relapses and delays worsening disability. Participants take one of the two drugs for several years, with an option…

This study aimed to test a drug called BAC in people with Alzheimer's disease or vascular dementia. The goal was to see if it could improve thinking and memory, and to check for side effects. However, the trial was withdrawn before any participants were enrolled, so no results ar…

This study tests an experimental daily pill (RO7269162) in 256 people who either have brain plaques but no symptoms, or have mild memory problems due to Alzheimer's. Participants take the pill or a placebo for about 1.5 years, with regular check-ups to monitor safety and brain ch…

This study tests whether a daily pill called buntanetap can help people with early Alzheimer's disease think more clearly and handle daily tasks better. About 760 adults aged 55-85 will take either the drug or a placebo for 18 months. Researchers will check memory, thinking, and …

This study tests an experimental drug called BIA 28-6156 in people with Parkinson's disease who have a specific change in the GBA1 gene. The goal is to see if the drug can delay the worsening of movement-related daily living skills over 78 weeks. About 237 participants will recei…

This study tests two newer multiple sclerosis drugs, ofatumumab and siponimod, against an older one, fingolimod, in 129 children aged 10 to 17. The goal is to see if the newer drugs are at least as good at preventing MS relapses. Participants take one of the three drugs for two y…

This early-stage study tests a gene therapy called AB-1001 in 5 adults with early Huntington's disease. The treatment is injected directly into the brain to potentially slow the disease. The main goal is to check safety, but researchers will also look at brain changes on MRI and …

This early-stage trial tests a gene therapy called PBFT02 for frontotemporal dementia (FTD) in people with specific genetic mutations. The therapy delivers a working copy of the GRN gene directly into the brain. The study involves 30 adults and primarily checks for safety and sid…

This early-stage study tests whether a new drug called QRL-201 is safe and tolerable for people with ALS (Lou Gehrig's disease). About 69 adults aged 18-80 with recent ALS symptoms will receive either the drug or a placebo. The main goal is to check for side effects, not to cure …

This phase 3 trial compares the experimental drug frexalimab to the approved drug teriflunomide in about 1,655 adults with relapsing multiple sclerosis. The main goal is to see if frexalimab reduces the number of relapses more effectively. Participants receive either frexalimab i…

This study tests an experimental drug called frexalimab in people with a type of progressive multiple sclerosis (MS) that is no longer causing relapses. The goal is to see if the drug can delay worsening disability compared to a placebo. About 943 adults aged 18 to 60 are taking …

This study tests a new maintenance dosing schedule for ofatumumab, a drug used to control relapsing multiple sclerosis (MS). Researchers want to see if the new schedule is as safe and effective as the current approved dose. About 196 adults with relapsing MS will take part, and t…

This study tests omaveloxolone, a drug already approved for adults with Friedreich's ataxia, in children aged 2 to 15. Researchers want to see how the drug moves through children's bodies and whether it is safe. The study involves two parts: a single dose followed by daily dosing…

This was a planned phase 2 trial to test IC14, a monoclonal antibody, in 50 people with rapidly progressing ALS. Participants would have received intravenous IC14 or placebo twice weekly for 12 weeks. The study was withdrawn before any patients were enrolled, so no data on safety…

This study planned to test an experimental drug called IC14 in people with rapidly progressing ALS. The drug was given by IV over two weeks, and brain scans measured inflammation. However, the trial was withdrawn before enrolling any participants, so no data on safety or effectiv…

This study tests a device that delivers specific light and sound patterns to the brain, aiming to slow the progression of mild-to-moderate Alzheimer's disease. About 670 participants will use the device at home for an hour daily over a year, with half receiving a sham (inactive) …

This phase 3 trial tests whether the oral drug masitinib can slow disability worsening in people with progressive multiple sclerosis who do not have relapses. About 800 participants will receive either masitinib or a placebo for 96 weeks. The main goal is to see if masitinib dela…

This study follows about 1,300 people with multiple sclerosis who are already taking ocrelizumab to see how safe and effective it is over many years. Participants continue their usual treatment, and researchers track side effects, disability changes, and brain scans. The goal is …

This study tests an oral drug called SKY-0515 in 120 adults with Huntington's disease. The goal is to see if it can lower harmful proteins in the blood, slow brain changes, and improve symptoms. Participants must be 25 or older with a confirmed genetic diagnosis and a certain lev…

This study tests whether a higher dose of the drug ocrelizumab can better control relapsing multiple sclerosis (MS) and delay disability compared to the standard dose. About 864 adults with relapsing MS will receive either the higher or standard dose every 24 weeks. The main goal…

This study is testing the drug ocrelizumab in 927 people with progressive multiple sclerosis (MS), a form of the disease that steadily worsens. Participants receive infusions every 24 weeks for about 4 years. The main goal is to see if the drug can stop or slow disability progres…

This study tests whether injecting a replacement enzyme directly into the eye can slow or stop vision loss in children with CLN2 Batten disease, a rare genetic disorder that causes blindness and brain damage. Five children aged 2 to 6 who already receive brain infusions of the en…

This study tests a single-dose gene therapy called LY3884963 in 35 people with frontotemporal dementia caused by GRN gene mutations. The therapy aims to raise levels of a missing protein (progranulin) in the brain. Participants receive the treatment via injection into the fluid a…

This expanded access program provides apitegromab, an experimental drug that blocks myostatin to help maintain muscle strength, to eligible patients with spinal muscular atrophy (SMA) before it is officially approved. Participants must be at least 2 years old and have a confirmed…

This early-stage study tests whether a new drug, prosetin, is safe for people with ALS (Lou Gehrig's disease) and healthy volunteers. About 72 participants will receive either the drug or a placebo to check for side effects and how the drug moves through the body. The goal is to …

This early-stage study tests an experimental cell therapy called P-CD19CD20-ALLO1 in 60 adults with multiple sclerosis. The main goal is to see if it is safe and how the body handles it. Researchers will also measure how long the cells last and how they affect the immune system.

This study tests whether a daily 10 mg pill called Xanamem can safely slow memory and function loss in people with mild or moderate Alzheimer's dementia. About 247 participants will receive either Xanamem or a placebo for 36 weeks, with an option to continue the drug for up to 10…

This early trial tests whether a transplant of umbilical cord blood can help people with ALS, a fast-progressing nerve disease. Eight adults will receive the transplant after a mild chemotherapy-like prep. Researchers will check safety and whether the treatment slows decline in m…

This study follows 403 adults and children with spinal muscular atrophy who are already taking risdiplam (Evrysdi) as prescribed by their doctor. Researchers will track side effects and how well the drug works over about two years. The goal is to see if risdiplam remains safe and…

This study tests whether regular warm-water baths can improve blood sugar control and brain energy use in healthy adults aged 65 and older who are at risk for Alzheimer's disease. Over 10 weeks, 60 participants will soak in warm water three times a week. Researchers will measure …

This study tests a new drug called PRI-002 in 304 people with mild memory problems or early Alzheimer's. The drug aims to break apart harmful protein clumps in the brain that are linked to Alzheimer's. Researchers want to see if it is safe and can slow down memory and thinking de…

This study tests a drug called SHP611, given as a spinal injection, in 36 children with late infantile metachromatic leukodystrophy (MLD), a rare and severe brain disease. The main goal is to see if the treatment helps children keep their ability to walk and move for as long as p…

This study tests whether blood plasma from young, healthy, and very fit donors is safe and can help people with early Alzheimer's disease. Sixty patients aged 50-75 will receive monthly transfusions of either this 'exercise plasma' or a saltwater placebo over a year. Researchers …

This study aimed to see if a mist-inhaled drug called RNS60 could help people with ALS, a nerve disease that weakens muscles. It planned to measure changes in daily function, breathing, and survival. However, the trial was withdrawn before enrolling any participants, so no result…

This Phase 2 trial is testing a new drug called NVG-2089 in 60 adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a condition where the immune system attacks nerves. The drug is designed to mimic a natural protein (IVIg) to reduce inflammation and improve nerve…

This study looks at how well ofatumumab (Kesimpta®) works for people with relapsing-remitting multiple sclerosis (RRMS) in real-life settings across Italy. About 379 adults already prescribed the drug will be followed for 12 months to measure relapse rates and thinking speed. The…

This study tests whether a home-based program combining cognitive exercises (like puzzles) with mild brain stimulation can improve thinking and memory in older adults with mild cognitive impairment or late-life depression. About 40 participants will use the program at home with h…

This study tests an experimental drug called Lu AF82422 in 64 people with multiple system atrophy (MSA), a rare and serious brain disease. The goal is to see if the drug can slow down the worsening of symptoms like movement problems and daily living difficulties. Participants rec…

This study tests whether deep brain stimulation (DBS) can improve thinking and memory in people with early Alzheimer's disease. Two participants will have electrodes implanted in a brain area that produces a key chemical for memory. The goal is to see if daily, one-hour stimulati…

This program offered vatiquinone, an experimental liquid medication, to patients with inherited mitochondrial diseases like Leigh syndrome who had already completed a previous safety study. The goal was to continue treatment for those who might benefit, but enrollment is now clos…

This study tests a custom-made drug called an antisense oligonucleotide (ASO) designed for one person with dentatorubral-pallidoluysian atrophy (DRPLA), a rare genetic disorder that affects movement and brain function. The drug aims to reduce the harmful effects of the mutated AT…

This study tested an experimental drug called ARGX-119 in 60 adults with ALS. The goal was to see if it was safe and could help with muscle function. The trial was stopped early because early results showed it was unlikely to make a meaningful difference. No safety concerns trigg…

This early-stage trial tests a single intravenous dose of IMS001, a stem cell product made from human embryonic cells, in 30 adults with multiple sclerosis who have not responded well to standard treatments. The main goal is to see if the treatment is safe and tolerable, while al…

This study tests whether a person's own stem cells can be safely injected into the spinal fluid to treat multiple system atrophy (MSA), a rare and serious brain disease. About 30 adults aged 30-80 with MSA will receive the treatment. The main goal is to check for side effects, an…

This study tests the drug risdiplam (Evrysdi) in infants up to 6 weeks old who have a genetic diagnosis of spinal muscular atrophy (SMA) but no symptoms yet. The goal is to see if early treatment can help them reach motor milestones like sitting without support. The trial involve…

This study tests a custom-made genetic medicine (called an antisense oligonucleotide) designed for one person with dentatorubral-pallidoluysian atrophy (DRPLA), a rare inherited brain disorder. The treatment aims to reduce seizures and improve quality of life. Only one participan…

This program provides early access to an experimental drug called CNM-Au8 for people with amyotrophic lateral sclerosis (ALS), a progressive nerve disease. Participants must be 18 or older and have a confirmed ALS diagnosis. The goal is to offer treatment to those who cannot join…

This Phase 2 trial tests an experimental drug called LY3541860 against a placebo in 63 adults with relapsing multiple sclerosis. The goal is to see if the drug can slow the appearance of new brain lesions seen on MRI scans. The study lasts about 9 months, with an additional 6 mon…

This program provides CNM-Au8, a suspension of gold nanocrystals, to up to 300 people with ALS. The main goal is to give access to the drug and monitor safety, not to test if it works. Participants must have a confirmed ALS diagnosis and be at least 18 years old.

This study tests whether lecanemab can slow memory and thinking decline in people with early Alzheimer's disease. About 1,900 participants received either the drug or a placebo for 18 months, followed by an open-label extension where everyone can get lecanemab. The main goal is t…

This Phase II trial tests whether high-dose vitamin D (4,000 IU daily) can correct deficiency and slow cognitive decline better than standard doses in 180 older adults aged 65-90. Participants include those with normal thinking, mild impairment, or early Alzheimer's. The study la…

This Phase 3 trial tests whether zilganersen (ION373) can improve or stabilize motor function in people with Alexander disease, a rare genetic brain disorder. Fifty-four participants aged 2 to 65 will receive either the drug or a placebo injected into the spine. The study measure…

This phase 2 trial is testing whether a combination of two drugs, dasatinib and quercetin, is safe and feasible for people with early-stage Alzheimer's or mild cognitive impairment. The drugs aim to clear aging 'senescent' cells that may contribute to brain damage. 48 participant…

This study tests whether high-dose nicotinamide (vitamin B3) is safe and can help people with dominant optic atrophy, a rare genetic disease that slowly damages the optic nerve and causes vision loss. Researchers will give 25 adults 3 grams of nicotinamide daily and monitor for s…

This Phase 3 trial is testing whether a higher dose of the drug ocrelizumab (Ocrevus) can better slow disability progression in people with primary progressive multiple sclerosis (PPMS). About 769 adults with PPMS are receiving either the standard approved dose or a higher dose b…

This phase 3 trial tests whether the drug tofersen can delay or prevent ALS in adults who carry a SOD1 gene mutation but have no symptoms yet. About 158 participants will receive either tofersen or a placebo, and researchers will track how many develop ALS within two years. The g…

This study looks at whether people over 50 with a stable, inactive form of secondary progressive multiple sclerosis can stop taking their disease-modifying drugs without getting worse. Researchers will track 250 participants for 2 years to see if stopping treatment leads to more …

This early-stage study aimed to test a single infusion of GC012F CAR-T cells in people with multiple sclerosis. The goal was to check safety and see if the treatment could control the disease. However, the trial was withdrawn before enrolling any participants, so no data was coll…

This study tests whether ATI-045 can safely reduce eczema symptoms like redness, itching, and skin patches in people with moderate-to-severe disease. About 110 adults who haven't had success with topical treatments will receive either the drug or a placebo. The main goal is to se…

This study tests whether adding sodium benzoate (a common food preservative) to brain stimulation therapy can improve thinking and memory in people with early Alzheimer's or mild cognitive impairment. 140 participants will receive two weeks of brain stimulation and then 24 weeks …

This study looks at how often older adults (62+) who are worried about memory loss should take dance or music classes to boost brain health and physical fitness. Over 6 months, 165 participants will attend 1, 2, or 3 group classes per week. Researchers will measure changes in mem…

This phase 2 trial tests whether glycerol phenylbutyrate (GPB) can slow corticobasal syndrome (CBS), a rare and fast-progressing brain disease. 32 adults with CBS will receive either GPB or a placebo for 26 weeks. The main goal is to see if GPB lowers levels of a nerve damage mar…

This pilot study tests whether combining intensive hand-arm and leg therapy with strength training can improve motor function in children with spinal muscular atrophy (SMA). Five children will attend one 6-hour session each weekend for 15 weeks. Researchers will check if the ther…

This early-phase study tests a lab-made protein (recombinant human serum albumin) in 30 people with mild to moderate Alzheimer's. Participants receive one of three doses to check safety and any effect on thinking skills. The goal is to see if this treatment can help control the d…

This study tests whether N-acetyl cysteine (NAC), a supplement, can protect the brain in people with progressive multiple sclerosis (MS). About 98 adults with primary or secondary progressive MS will receive either NAC or a placebo for 15 months. Researchers will measure brain sh…

This study looks at whether switching from anti-CD20 drugs (like ocrelizumab) to cladribine can help restore immune function and reduce infections in people with relapsing multiple sclerosis. About 70 participants will be followed for 2 years. The goal is to see if the switch imp…

This early-phase trial tests whether a patient's own bone marrow stem cells, injected into the spinal fluid, can repair nerve damage caused by progressive multiple sclerosis. The study involves 18 adults with secondary or primary progressive MS. Researchers will measure changes i…

This study is testing a new device called a multichannel vestibular implant for people who have lost most or all of their balance function due to inner ear damage. The implant electrically stimulates the balance nerve to help improve stability and vision during movement. Up to 30…

This study tests a new medicine called exidavnemab in people with mild to moderate Parkinson's disease or multiple system atrophy. The main goal is to check if the drug is safe and how the body processes it. Participants will receive either the drug or a placebo, and researchers …

This study tests a new treatment for ALS (Lou Gehrig's disease) using stem cells taken from the patient's own belly fat. The cells are injected into the fluid around the spine every 3 months for a year. The goal is to see if this treatment is safe and can slow down the disease. A…

This clinical trial tests whether ibudilast (MN-166), a drug previously used for asthma, can slow the progression of amyotrophic lateral sclerosis (ALS). The study involves 234 adults with ALS, who will receive either ibudilast or a placebo for 12 months, followed by a 6-month op…

This study tests lecanemab, an antibody that targets amyloid plaques in the brain, in 40 people who carry a gene mutation that causes early-onset Alzheimer's. Participants previously received another anti-amyloid drug and will now receive lecanemab to see if it can fully clear am…

This expanded access program gave a single patient with Leber Hereditary Optic Neuropathy (a genetic cause of vision loss) an experimental gene therapy called GS010. The treatment was injected into both eyes to test safety. Only one person was involved, so the results are very li…

This study looks at whether terazosin, a drug usually used for high blood pressure, can slow the progression of Parkinson's disease. Researchers are tracking changes in heart and brain scans of 15 people who are either in early stages or at high risk for Parkinson's. The goal is …

This phase 2 trial tests whether carvedilol, a drug usually used for heart conditions, can slow the loss of dopamine transporters in the brain and delay Parkinson's symptoms. It follows 15 people with REM sleep behavior disorder and other early Parkinson's risk factors over three…

This study tests a personalized drug called nL-TUBB4-001, designed specifically for one child with TUBB4A-related leukodystrophy, a rare genetic disease that damages the brain. The drug is an antisense oligonucleotide, which aims to correct the genetic error. The trial will monit…

This phase 2 trial tests whether high-dose chemotherapy followed by a stem cell transplant can stop the immune system from attacking the nervous system in people with autoimmune neurologic diseases like multiple sclerosis and stiff person syndrome. The treatment aims to weaken th…

This study tests whether adding daratumumab back to pomalidomide and dexamethasone can improve complete remission rates in 15 adults with relapsed or refractory AL amyloidosis who have already received daratumumab. Participants receive the three-drug combination to control the di…

This phase 3 study tests an oral medication called IMU-838 against a placebo in about 1,100 adults with relapsing multiple sclerosis (MS). The goal is to see if the drug can reduce the number of relapses and new brain lesions over 72 weeks. Participants must be 18-55 years old wi…

This Phase 3 trial tests whether IMU-838 (vidofludimus calcium) can reduce relapses and brain lesions in adults with relapsing multiple sclerosis. Over 1,100 participants are randomly assigned to receive either the drug or a placebo for up to 72 weeks. The study is active but no …

This phase 3 trial tests whether ocrelizumab (Ocrevus) can slow disability progression in adults with primary progressive multiple sclerosis (PPMS). Over 1,000 participants receive either the drug or a placebo. The main goal is to see if the drug delays worsening of hand function…

This Phase 2 trial tests whether a sleep-deepening drug (lower-sodium oxybate) or a nerve-stimulating device (non-invasive vagus nerve stimulation), or both, can help clear amyloid-beta protein from the brain in people with cerebral amyloid angiopathy (CAA). Sixty participants wi…

This study tests whether a smartphone app that coaches older adults to eat more protein can help them maintain muscle mass and strength. Researchers will enroll 140 participants who are open to changing their diet and using an app. The app provides personalized nutritional coachi…

This Phase 2 trial tests whether infusions of special immune cells (tolerogenic dendritic cells) can reduce brain lesions and relapses in people with relapsing-remitting multiple sclerosis. The 45 participants also take standard MS drugs. The study aims to see if this cell therap…

This study tests a surgical procedure that aims to improve the brain's waste-clearing system in people with Alzheimer's disease. The surgery involves relieving pressure on lymphatic vessels in the neck and connecting a lymph node to a vein to help drain harmful proteins. Research…

This study tests an experimental drug called ION363 in people with a rare, inherited form of ALS caused by FUS gene mutations. The goal is to see if the drug can slow the disease and help people live longer. About 89 participants will receive the drug via spinal injection. This i…

This study tests a stem cell transplant using a milder chemotherapy-like regimen to treat children and young adults (up to age 28) with various immune system disorders. The goal is to help the donor stem cells settle in the body with fewer side effects. The study involves 20 part…

This long-term study is testing higher doses of nusinersen (Spinraza) in people with spinal muscular atrophy who already completed a previous nusinersen study. The main goal is to check safety over several years, including side effects, heart health, and growth. Participants rece…

This clinical trial is testing an oral drug called NUZ-001 in 160 people with ALS. Participants take the drug or a placebo daily for 36 weeks. The study measures how the disease progresses using a scale of physical function and survival. The goal is to see if NUZ-001 can slow ALS…

This study tests the long-term safety of the drug tolebrutinib in 2,500 adults with relapsing or progressive multiple sclerosis. Participants previously took part in earlier trials and will continue taking tolebrutinib or a placebo for up to several years. The goal is to see if t…

This study tests whether olive pomace oil, a type of olive oil, can lower brain inflammation in people with early-stage Alzheimer's. Researchers will give 40 Alzheimer's patients and 40 healthy adults meals containing either pomace oil or a different oil, then measure blood marke…

This phase 2 trial is testing whether adding a new drug called E2814 to the existing Alzheimer's drug lecanemab can better slow the disease in people with early Alzheimer's. The study involves 105 participants and will measure changes in tau protein levels in spinal fluid and bra…

This trial provides expanded access to RAPA-501, a therapy made from a patient's own immune cells, for people with ALS. The goal is to control the disease and slow its progression. Participants must be 18 or older and have a confirmed ALS diagnosis.

This phase 3 trial tests a gene therapy called NR082 for Leber's hereditary optic neuropathy (LHON), a genetic condition that causes rapid vision loss. About 95 people aged 12 to 75 with a specific ND4 mutation will receive a single injection of the therapy or a sham procedure. T…

This study tests whether experimental drugs can slow down memory and thinking problems in people who have a gene mutation that causes Alzheimer's disease. About 490 adults aged 18-80 with this genetic risk are taking either a study drug or a placebo. The goal is to see if the dru…

This study tests whether two drugs, E2814 and lecanemab, can slow the progression of Alzheimer's in people who carry a gene mutation that causes the disease. About 197 participants will receive either the drugs or a placebo over 2 to 4 years. Researchers will measure changes in t…

This study aimed to test whether stem cells from amniotic fluid, injected into the spinal fluid, could safely help people with progressive multiple sclerosis (MS). The trial was designed for adults aged 18–60 with primary or secondary progressive MS. However, the study was withdr…

This study tests whether the drug usnoflast can slow the progression of ALS, a severe nerve disease that causes muscle weakness and breathing problems. About 240 adults with ALS will receive either usnoflast or a placebo for 36 weeks. Researchers will measure changes in daily fun…

This early-phase trial planned to test a one-time infusion of genetically modified immune cells (CAR-T cells) targeting CD19 in people with several autoimmune diseases, including lupus and multiple sclerosis. The goal was to see if it was safe and could reduce harmful antibodies.…

This study tests whether ocrelizumab is safer and more effective than fingolimod for children and adolescents (ages 10 to under 18) with relapsing-remitting multiple sclerosis. Participants receive either drug and are monitored for relapses and brain lesions over at least 24 week…

This early-stage trial tests a gene therapy called AAV2-GDNF for multiple system atrophy (MSA), a rare and serious brain disorder. Nine adults with MSA will receive either the gene therapy or a sham surgery. The main goal is to check safety, but researchers will also look for any…

This study tests a new medicine called ONO-2020 in 240 people with mild to moderate Alzheimer's disease. The goal is to see if it can safely improve memory and thinking skills. Participants will receive either the drug or a placebo for 26 weeks, and researchers will track side ef…

This study is testing whether the drug ocrelizumab (Ocrevus) can improve signs of inflammation in the spinal fluid of people newly diagnosed with relapsing multiple sclerosis (MS) or a high-risk first attack (clinically isolated syndrome). Thirty participants will receive ocreliz…

This early-stage trial tests a new treatment called KYV-101 for people with progressive multiple sclerosis (MS) that hasn't improved with standard treatments. KYV-101 is a CAR T-cell therapy made from a patient's own immune cells, designed to attack the cells causing inflammation…

This study tests a new medicine called PYC-001, given as an injection into the eye, for people with a genetic condition that damages the optic nerve (OPA1 optic atrophy). The main goal is to check if the treatment is safe and tolerable. About 18 adults will receive a single dose,…

This study tests a program that uses a smartphone app, an activity tracker, phone coaching, and rewards to help adults in rural Kentucky eat more fruits and vegetables, cut down on fat, get more exercise, and spend less time on screens. About 279 participants will use the app and…

This study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…

This study tests an AI tool called AIDP that analyzes MRI scans to help diagnose Parkinson's disease and two similar conditions (MSA and PSP). Researchers at 21 sites will compare the AI's diagnosis to that of movement disorder specialists. The goal is to see if the tool can impr…

This study uses special brain scans (PET imaging) to measure amyloid buildup—a protein linked to Alzheimer's—in healthy older adults, people with mild memory problems, and those with dementia. Participants receive scans every 2-3 years for up to 20 years to see how amyloid change…

This large study tests whether a simple iPad-based cognitive test, called MyCog, can help primary care doctors detect early dementia and cognitive impairment in underserved communities. Over 57,000 older adults from 24 clinics will take the test during routine visits. The goal is…

This study explores whether a self-administered digital test called eSAGE, combined with information from electronic health records and machine learning, can help detect early signs of cognitive impairment, including dementia and Alzheimer's disease. Researchers will analyze data…

This study tests a new radioactive tracer called Fluselenamyl for PET scans to detect beta-amyloid plaques in the brain, a hallmark of Alzheimer's disease. Researchers will check its safety and how well it works in 60 healthy volunteers and people with mild cognitive impairment o…

This study aimed to see if a special fMRI scan (fMRI-SAM) could help detect Alzheimer's disease early. Researchers planned to compare brain activity in 25 people with Alzheimer's, 25 with mild memory problems (MCI), and 60 healthy adults. The goal was to find differences that mig…

This early-phase study tests whether a single injection of pramlintide, a diabetes drug, can temporarily increase levels of Alzheimer's-related proteins in the blood, potentially revealing early signs of the disease. Researchers will measure changes in beta-amyloid and tau protei…

This study compares a new ultra-high resolution PET/CT scanner, the NeuroEXPLORER, with standard clinical PET/CT scanners for imaging the head and neck. Researchers aim to see if the new device provides more detailed images to improve diagnosis of conditions like dementia, Parkin…

This study is developing a web-based app that analyzes how you speak and remember things to quickly detect early cognitive problems like dementia or Alzheimer's. Researchers will enroll 500 people (healthy adults over 45 and those already diagnosed with mild cognitive impairment …

Stanford University is developing a mobile app that uses video of a simple physical test (the Short Physical Performance Battery) to assess physical and cognitive function in older adults. The study will collect video data from 30 healthy volunteers to train the app's AI. The goa…

This study is testing whether a simple saliva sample can help diagnose amyotrophic lateral sclerosis (ALS). Researchers will analyze RNA in the saliva of 653 people, including ALS patients and healthy volunteers. If the test works, it could offer a faster, less invasive way to di…

This study is looking for better ways to diagnose Parkinson's disease using samples that are easy to collect, like blood, skin, and nasal swabs. Researchers will compare these samples from 340 people, including those with Parkinson's, Alzheimer's, and healthy volunteers. The goal…

This study tests whether an AI tool can help radiologists read brain CT and MRI scans more accurately and quickly. Researchers will compare how well doctors, AI alone, and doctors using AI together can spot abnormalities, urgent findings, and classify diseases. The goal is to red…

This study uses a special brain scan called DaTscan to look at how certain brain diseases affect the brain. Researchers will scan 500 adults with conditions like Parkinson's disease, dementia, mild cognitive impairment, or REM sleep behavior disorder. The goal is to see if DaTsca…

This study looks at whether a special brain scan called diffusion tensor imaging (DTI) can help doctors find Krabbe disease in newborns and decide who needs urgent treatment. About 100 babies with a positive newborn screen or family history of Krabbe disease will be scanned and f…

This study is testing whether a blood test can identify people who have Alzheimer's-related brain changes, even if they have no memory problems. Researchers will enroll 2000 adults aged 50-80, some with risk factors like family history. The goal is to see if the blood test can ac…

This study tests an 8-week group program called My Healthy Brain for adults aged 50 and older who have memory concerns but not dementia. The program teaches about lifestyle factors like exercise, sleep, and diet that may help prevent dementia. Researchers want to see if the progr…

This study tests whether metformin, a drug used for diabetes, can prevent Alzheimer's dementia in people with mild cognitive impairment (MCI). Over 18 months, 326 overweight adults aged 55-90 with MCI will receive either metformin or a placebo. Researchers will track memory, brai…

This study tests whether following the MIND diet for 2 to 3 years can slow cognitive decline and reduce dementia risk in people aged 55 and older who have had an ischemic stroke. The MIND diet combines elements of the Mediterranean and DASH diets, with extra emphasis on leafy gre…

This study tests whether a pharmacist-led program to stop certain medications (anticholinergics) can lower dementia risk in older adults. 344 participants aged 65+ who take these drugs will be followed for 2 years, comparing cognitive changes and quality of life between those who…

This 7-year study tests whether a combination of mild electrical brain stimulation (tDCS) and computer-based memory exercises can slow mental decline and prevent Alzheimer's dementia. It involves 375 older adults with mild cognitive impairment or depression (both risk factors for…

This study tests if a drug called dalargin can prevent serious organ problems like kidney injury, lung failure, or heart damage after major abdominal surgery. About 200 adults having high-risk surgery will get either dalargin or a placebo for 3 days. The goal is to see if dalargi…

This study tests whether donanemab, a monthly infusion, can delay or prevent memory and thinking problems in people who have early signs of Alzheimer's disease but no symptoms yet. About 3000 participants with a positive blood test for Alzheimer's-related proteins are being follo…

This study looks at whether pramipexole, a drug used for restless leg syndrome, can ease leg symptoms in women with X-linked adrenoleukodystrophy (ALD). About 24 women will take the drug or a placebo for two months. The goal is to see if it improves sleep, walking, and quality of…

This study tests whether a 24-week physical therapy program can help people with multiple sclerosis become more physically active. Forty participants will receive tailored exercise support and education. The goal is to see if this approach is feasible and helps manage MS symptoms…

This study tests whether a device that plays brief, soft sounds during deep sleep can enhance brain wave activity in people with mild cognitive impairment due to Alzheimer's disease. Participants use the device at home each night for three months, with an optional three-month ext…

This pilot study explores whether non-invasive electrical stimulation of the spinal cord, combined with hand and arm exercises, can improve upper limb function in people with multiple sclerosis. Participants use a home device with help from a partner over 8 weeks. The study focus…

This study tests a web-based support program called Hospital GamePlan4Care for caregivers of veterans with dementia who are discharged from skilled nursing facilities to home. Fifty-five caregivers will receive either the program (website, emails, and phone coaching) or basic hea…

This study tests whether a special therapy using sights, sounds, touch, and other senses can help people with moderate Alzheimer's think clearer, feel calmer, and behave better. It also looks at whether this therapy reduces stress for their caregivers. Twenty-four people aged 65 …

This pilot study tests a mobile app called Brain CareNotes designed to reduce the burden on unpaid caregivers of people with Alzheimer's or related dementias who live in rural areas. About 60 caregivers will use either the Brain CareNotes app or a basic education app for six mont…

This pilot study tests whether one-on-one peer support sessions can help people with relapsing-remitting multiple sclerosis stay on their prescribed medications. Sixty adults will be randomly assigned to receive either standard care or three hour-long sessions with a trained peer…

This study looks at the long-term safety of valbenazine for people with Huntington disease who have involuntary jerking movements (chorea). It includes 7 participants from Canada who were in a previous valbenazine study. Everyone gets the drug, and researchers track side effects …

This study tests whether a safe, painless brain stimulation technique called tDCS can improve verbal learning in people with Alzheimer's disease. Researchers will compare active stimulation to a sham (fake) version in 90 participants with typical or language-based Alzheimer's. Th…

This study tests whether a wearable light device can help improve sleep and daily rhythms in people with Alzheimer's who have sleep problems. Researchers will also use activity trackers and blood tests to better understand the disease. About 162 participants will try the light th…

This study planned to test whether automated music therapy could help manage agitation and sleep problems in people with severe Alzheimer's living in nursing homes. An actigraph would detect sleep issues and trigger music sessions automatically. The trial was withdrawn before any…

This study looks at whether special video games (serious games) that combine physical and mental exercises are a good value for managing Alzheimer's disease. About 136 people with mild to moderate Alzheimer's will either play these games with a therapist or receive usual care. Re…

This study tests a telemedicine program called FOCUS that helps advanced cancer patients manage common symptoms like trouble sleeping, worry, tiredness, and low mood. The program uses counseling techniques delivered through a phone app. Researchers will enroll 120 adults with adv…

This study tests a personalized workplace intervention for 124 Dutch workers with Parkinson's disease, cerebellar ataxia, hereditary spastic paraparesis, or slowly progressive neuromuscular/mitochondrial disorders. A trained facilitator helps employees and their managers identify…

This study tests whether combining music-based movement cues (patterned sensory enhancement) with mild brain stimulation can improve arm and hand function in people with corticobasal syndrome, a rare brain disorder. Twenty participants will be split into two groups: one receiving…

This study tests whether a guided internet-based physical activity program can improve cognitive processing speed in people with multiple sclerosis. 280 participants who have mild walking difficulties and slowed thinking will be randomly assigned to either the exercise program or…

This study tests if a gentle, non-invasive nerve stimulation device can help manage symptoms of multiple sclerosis (MS), like fatigue and pain. Thirty women with MS will use the device at home for a few weeks. The goal is to see if it's practical and if it reduces symptom burden,…

This study tests a new way to match dementia caregivers with each other for emotional support using a computer algorithm. Researchers want to see if matching based on personal preferences leads to better satisfaction and less stress than random matching. About 355 caregivers of p…

This phase 2 trial tests whether a single low-dose ketamine infusion can reduce fatigue in people with multiple sclerosis. About 110 adults with MS-related fatigue will receive either ketamine or a mild sedative (midazolam) as a placebo. The study measures changes in fatigue scor…

This study was designed to test whether a reusable pouch called DoddleBags could help people with Huntington's disease eat more easily and safely. The pouch holds pureed food and can be used with an anti-choking cap or spoon attachment. The trial was withdrawn before any particip…

This study tests whether using a device that delivers light and sound stimulation for 60 minutes each day is safe and practical for people with mild Alzheimer's. Fifteen participants will use the device at home for 6 to 9 months. The main goals are to see if people can stick with…

This study tests whether adding a non-invasive brain stimulation technique called transcranial magnetic stimulation (TMS) to speech therapy can improve language skills in people with primary progressive aphasia (PPA), a condition that slowly damages language areas of the brain. A…

This study tests whether combining transcranial magnetic stimulation (TMS) with virtual reality exercises and physical therapy can improve symptoms like balance, fatigue, and thinking in people with multiple sclerosis. Thirty participants will receive both real and sham TMS in a …

This study tests whether a gentle, low-level electric current applied to specific brain areas can improve speech and language difficulties in people with primary progressive aphasia (PPA) and progressive apraxia of speech (PAOS). The treatment is called high-definition transcrani…

This study tests whether an oral oil containing THC and CBD can reduce agitation in people with dementia who are eligible for hospice care. About 120 participants will receive either the active drug or a placebo for 12 weeks. The main goal is to see if agitation scores improve af…

This pilot study aimed to test whether immersive virtual reality (VR) exercises could help people with multiple sclerosis who experience dizziness, balance issues, and fatigue. Participants would have been randomly assigned to either VR-based vestibular rehab or conventional exer…

This study tests a headset that delivers flashing lights and clicking sounds at 40 times per second (40 Hz) for one hour daily. Researchers want to see if this stimulation improves visual processing and thinking in 20 people aged 60+ with Alzheimer's disease. Participants will ha…

This study tests whether a home exercise program combined with a gentle brain stimulation technique (tDCS) can reduce fatigue in people with multiple sclerosis. Sixty participants will either get real tDCS or a sham version alongside their exercises. The goal is to see if the com…

This study tests a biodegradable tube that is placed over a cut nerve during a leg biopsy. The goal is to see if it is safe and reduces common side effects like pain, redness, and swelling. Twenty adults with various nerve conditions are taking part, and half will get the tube wh…

This study tests whether a 12-week strength and functional exercise program, done at home via video calls with a physiotherapist, can improve walking, balance, and daily life in people with Hereditary Spastic Paraplegia (HSP). Twenty participants aged 16 to 70 will each experienc…

This study tests an online program called SAGE LEAF that teaches positive emotion skills to family caregivers of people with dementia. Over 6 weeks, participants learn techniques like gratitude and mindfulness through short lessons and daily practice. The goal is to see if the pr…

This pilot study tested whether a non-invasive brain stimulation technique called tDCS could improve cognitive and motor functions in older adults with mild Alzheimer's disease living in supportive housing. Eleven participants received either real or sham stimulation over 10 sess…

This study tests a 6-week online program called Learning Skills Together for family caregivers of people with Alzheimer's or related dementias. The program includes weekly group discussions and a workbook covering topics like communication, medication management, and home safety.…

This study tests a new, non-invasive brain stimulation technique called Temporal Interference Stimulation (TIS) in 40 people with early-stage Alzheimer's. Participants receive either real or sham stimulation for 2 weeks. Researchers will check if it improves thinking and memory r…

This study tests whether a non-invasive brain stimulation technique called paired associative stimulation (PAS) can improve memory and thinking in 150 older adults with mild cognitive impairment (MCI), a condition that often leads to Alzheimer's. Participants receive daily sessio…

This study tests whether special lights placed over doorways can help reduce nighttime falls in assisted living residents with Alzheimer's or related dementias. The lights are low-intensity and outline the bathroom or entry door, providing visual cues to improve balance. Research…

This study tests a 12-week online program for mothers of infants (12-36 months old) with SMA Type 1. The program aims to teach mothers how to support their baby's development and improve their own knowledge. Thirteen mothers will take part, with 10 receiving the program and 3 rec…

This study tests whether giving caffeine to adults aged 70 and older after major surgery can lower their risk of postoperative delirium—a state of sudden confusion. Researchers will compare low-dose and high-dose caffeine against a placebo in 250 participants. The goal is to see …

This study looks at whether adding a daily 30-minute muscle stimulation session can improve pain control and quality of life for people who already have a spinal cord stimulator (BurstDR) for chronic back pain. Sixty adults with failed back surgery syndrome or persistent spinal p…

This study tests a cognitive rehabilitation program called CIRCuiTS, adapted for people with Multiple Sclerosis (MS). Twenty-four participants will either start the program right away or after a 13-week wait. The program involves up to 36 hours of therapist-led and independent se…

This study tests whether deutetrabenazine can improve speech clarity and walking ability in people with Huntington disease. About 30 adults with early to moderate symptoms will take the drug and be evaluated using speech tests and motion capture technology. The goal is to see if …

This study tests a personal health app called MS FIT that lets people with multiple sclerosis log falls and near-falls, view their health data, and share it with their doctor. The goal is to improve communication about fall risks and provide educational tips. About 100 participan…

This study tests a structured care pathway for treating agitation and aggression in people with Alzheimer's disease. The pathway combines personalized activities with medication guidelines to reduce symptoms and avoid using too many drugs. Researchers will compare this approach t…

This study tests whether shining near-infrared light on the head (a device called NirsCure) can safely help people with mild-to-moderate Alzheimer's disease. 38 participants will either get real light or a sham treatment for 16 weeks, then everyone can get the real light for up t…

This study tests an 8-week program that helps people with mild dementia and their caregivers identify and use their strengths. The program includes workshops and a biography activity led by trained volunteers. Researchers will measure changes in thinking skills and caregiver conf…

This study looks at whether a ketogenic diet (high-fat, low-carb) is practical and safe for people with early-stage Alzheimer's disease over one year. The diet may provide an alternative energy source for the brain and reduce inflammation. Researchers will track diet adherence, b…

This study tests whether using a mechanical insufflation device (BiWaze Cough) twice daily for 6 months can slow the decline in cough strength in 20 people with early ALS. Participants will use a facemask or mouthpiece to help inflate their lungs fully before coughing. Researcher…

This study tests a tablet-based app called the Digital Memory Notebook (DMN) to help older adults with mild memory problems or early Alzheimer's manage everyday tasks like appointments and medications. Twenty participants will learn to use the app over six weekly sessions, then c…

This study looks at whether improving diet quality and reducing calories can help physical function, thinking, pain, fatigue, mood, and anxiety in 100 adults with relapsing-remitting or secondary progressive multiple sclerosis. Participants receive prepared meals and behavioral s…

This small, early-stage study tested a high-CBD, low-THC liquid spray for 8 weeks in 12 older adults with mild cognitive impairment or mild-to-moderate Alzheimer's who also had significant anxiety or agitation. The goal was to see if the treatment could reduce these behavioral sy…

This study tests whether a 4-week telerehabilitation program can improve balance and quality of life in 36 people with multiple sclerosis or Parkinson's disease. Participants do balance exercises at home while monitored by a hospital physiotherapist. The results are compared to s…

This study tests whether a 9-week online cognitive behavioral therapy program can improve sleep in people with multiple sclerosis (MS). About 550 participants in Norway will either receive the digital therapy or digital education about insomnia. The main goal is to see if the the…

This study tests whether a drug called istradefylline, combined with short periods of breathing low-oxygen air (acute intermittent hypoxia), can improve breathing in people with ALS. About 40 adults with ALS and healthy volunteers will take part. The goal is to see if this combin…

This study tests whether a home-based telenursing program, led by a specialist nurse, can improve quality of life and reduce complications like falls for people with atypical parkinsonism (MSA or PSP). About 164 participants will receive proactive and reactive remote monitoring a…

This study tests whether educational programs about exercise, Mediterranean diet, and mental strategies can improve quality of life and reduce fatigue in women with relapsing-remitting multiple sclerosis. About 60 participants will be assigned to either supervised in-person sessi…

This study looks at whether strength training done during a specific phase of the menstrual cycle can reduce fatigue and improve quality of life in women with relapsing-remitting multiple sclerosis. Twenty women with MS and a matched group without MS will take part. Researchers w…

This study tests whether a non-invasive brain stimulation technique called theta-burst stimulation (TBS) can improve cognitive function in people diagnosed with young-onset Alzheimer's disease (before age 65). Seventy participants will receive TBS to a specific brain area, and re…

This study tests a 12-week program called PERSEVERE for 502 family caregivers of people with Lewy body dementia (LBD). Caregivers are matched with a trained peer mentor who guides them through lessons on LBD and provides support. The goal is to see if this reduces caregiver strai…

This study tests if learning memory techniques (like mnemonics) can improve thinking and memory in adults over 50 who have mild memory concerns. 80 participants will either take memory training or just get information. The goal is to see if training helps and if benefits last up …

This study tests a website tool called WeCareToFeedDysphagia to see if it reduces stress and burden for people caring for older adults with Alzheimer's disease or related dementias who also have trouble swallowing. About 800 caregivers will be split into two groups: one gets acce…

This study compares qigong exercises to standard physical therapy for people with multiple sclerosis. Thirty-six adults with mild to moderate MS will do either qigong or conventional rehab three times a week. Researchers will measure changes in balance, mood, and overall well-bei…

This study looks at whether a gentle brain stimulation technique (tDCS) combined with a special exercise program can reduce symptoms of spinocerebellar ataxia, a disease that affects coordination and balance. Fifteen adults who can walk (with or without help) will receive either …

This study looks at whether online community support and telemedicine can improve quality of life for people with Parkinson's disease, Lewy body dementia, and related conditions, as well as their caregivers. About 632 participants will receive palliative care training for their d…

This study tests whether daily exposure to a flickering gamma light is safe and tolerable for people with Parkinson's disease who experience freezing of gait—a sudden inability to step forward. Researchers will monitor side effects and see if the light therapy reduces freezing ep…

This study tests a set of virtual reality exergames in the Metaverse to help people with neurological conditions like multiple sclerosis, Parkinson's disease, stroke, and traumatic brain injury improve their cognitive skills. 25 participants will try games like virtual cooking an…

This study tests whether coaching for people with dementia and their caregivers can improve care and reduce future emergency room visits. About 19,200 participants aged 66 and older with Alzheimer's or related dementias will receive different combinations of support after an ER v…

This study tests whether monthly nurse-led coaching sessions over a year can help people with mild cognitive impairment or dementia and their caregivers. Researchers will track symptoms, quality of life, and how well care plans are documented. The goal is to improve supportive ca…

This study tests whether a wearable device, used at home alongside pelvic floor therapy, can help people with multiple sclerosis manage bladder problems. Twenty women with MS will use the device for three months. The main goal is to see if the approach is practical and easy to us…

This pilot study tests whether using a robotic glove for 20 minutes a day, 5 days a week, can improve quality of life, grip strength, and fine motor control in people with ALS. Five participants will use the glove at home over 8 weeks, with some in-person and telehealth check-ins…

This study tests whether education from a nurse – either in person or through tele-nursing (like WhatsApp) – can help people with multiple sclerosis feel less tired, have less pain, sleep better, and get fewer urinary tract infections. About 96 adults with relapsing-remitting MS …

This study tests whether wearing a special helmet that shines near-infrared light on the head can help brain cells work better and protect themselves. About 100 people with early to mid-stage dementia will wear the helmet regularly for 8 weeks. Researchers will check memory, thin…

This study tests whether virtual reality (VR) reminiscence therapy can reduce behavioral problems and improve quality of life in 50 nursing home residents with mild to moderate Alzheimer's disease. Participants will use VR to explore familiar heritage sites, aiming to trigger pos…

This study from Yale University will test whether listening to live music can reduce anxiety and improve brain activity in people with early Alzheimer's disease, dementia, or mild cognitive impairment, along with their caregivers. Sixty pairs (patient and caregiver) will attend b…

This study is testing a device called MemorEM, which is a cap that sends low-level electromagnetic waves to the head. The goal is to get feedback from 1,000 patients with neurological diseases like Alzheimer's or Parkinson's, and their caregivers, on how easy the device is to use…

This study looked at whether sunlight exposure therapy could improve sleep problems in people with Alzheimer's disease. Sixty participants with mild Alzheimer's and sleep issues received a health education plan on sun exposure and were followed for 14 days. The goal was to see if…

This study tests whether a home-based brain stimulation device (tDCS) combined with activity therapy can help improve cognitive and language problems in people with stroke, brain tumors, or neurodegenerative conditions like Parkinson's or Alzheimer's. Fifty-five participants will…

This study tests a program called FACE-Rare, designed to support family caregivers of children with rare, life-limiting diseases. The program includes three sessions to help families prepare for future medical decisions and improve their quality of life. Researchers will compare …

This early-stage study tests whether two drugs, dasatinib and quercetin, are safe and practical for people with mild cognitive impairment or Alzheimer's disease. The drugs aim to clear aging cells that may contribute to brain decline. Twenty participants aged 55 and older will be…

This study explores whether art therapy can help people with progressive supranuclear palsy (PSP) feel better and improve their daily life. Ten participants will take part in art sessions, and researchers will measure changes in quality of life, mood, and caregiver stress. The go…

This study follows 25 people with spinocerebellar ataxia type 7 (SCA7) for up to 5 years to learn how the disease changes vision, coordination, and thinking. Participants will have yearly eye exams, brain scans, and neurological tests. No treatment is given; the goal is to gather…

This study follows 125 people with Parkinson's disease or related conditions over two years. Researchers use special brain scans to measure changes in a chemical called acetylcholine, which is linked to walking problems, falls, and thinking skills. The goal is to understand how t…

This study follows 35 children with CLN2 disease (a rare, severe brain disorder) who are taking cerliponase alfa (Brineura). Researchers will monitor for side effects and serious reactions over time. The goal is to better understand the long-term safety of this enzyme replacement…

This study looks at how much of the multiple sclerosis drug ofatumumab gets into breast milk. About 24 women with relapsing MS who are breastfeeding and starting or restarting ofatumumab will provide milk samples. The goal is to measure drug concentrations, which may help guide f…

This study looks at two new ways to stage amyotrophic lateral sclerosis (ALS) based on key disease milestones. Researchers will check how well these systems work in 50 patients and see if adding a blood marker called neurofilament can improve tracking of the disease. The goal is …

This study aimed to see if Alzheimer's disease affects the nerves in the gut, similar to what happens in Parkinson's disease. Researchers planned to take extra colon biopsies during routine colonoscopies from people with Alzheimer's, Parkinson's, and healthy individuals to compar…

This study tests a short guide called the 'Jumpstart Guide' to help doctors have better conversations with dementia patients and their families about healthcare goals. Over 1,800 patients and their caregivers are taking part. Researchers will compare whether those whose doctors u…

This study aims to improve how doctors test for autonomic failure, a condition where the body's automatic functions like blood pressure control don't work properly. Researchers will use advanced imaging, sweat tests, and skin biopsies in up to 89 adults with Parkinson's disease, …

This study looks at how adults at risk for Alzheimer's disease react after learning their amyloid and tau biomarker test results. Researchers will track changes in distress, stigma, quality of life, and future planning over time. The goal is to understand the psychological and be…

This study follows 20,000 healthy Chinese adults aged 40-75 living at various altitudes to see if chronic low oxygen levels increase the risk of multiple system atrophy (MSA), a rare and fatal brain disease. Participants undergo checkups and overnight oxygen monitoring, then are …

This study tracks a protein called neurofilament light chain in the blood of 342 people who carry genetic mutations linked to frontotemporal dementia (FTD). Participants provide blood samples every three months for three years, often from home. The goal is to see if this biomarke…

This study aims to identify biomarkers—biological clues in the body—that can help distinguish between Parkinson's disease and similar conditions like progressive supranuclear palsy and multiple system atrophy. Researchers will follow people with early-stage parkinsonism and healt…

This study looks at how many women with multiple sclerosis (MS) use the drug interferon-beta during the second and third trimesters of pregnancy in Finland and Sweden. Researchers want to know if there are enough cases to study whether the drug affects pregnancy outcomes like bir…

This study follows 1,500 volunteers with normal memory, mild cognitive impairment, or Alzheimer's over several years. Researchers use brain scans, memory tests, and blood samples to track how the disease progresses. The goal is to find better ways to diagnose and treat Alzheimer'…

This study is observing 217 people with ALS and related conditions like frontotemporal dementia and hereditary spastic paraplegia. Researchers aim to connect each person's genetic makeup with their symptoms and find biological markers in blood and spinal fluid. No new treatments …

This study looks at people with ALS and similar diseases like frontotemporal dementia and hereditary spastic paraplegia. Researchers want to understand how genes affect the disease and find biological markers (biomarkers) to help develop future treatments. About 708 participants,…

This study investigates how genetic, lifestyle, and biological factors relate to memory and thinking problems in people over 60 with Alzheimer's disease, Parkinson's disease, or mild cognitive impairment. Researchers will use brain scans, spinal fluid and blood tests, and data fr…

This study enrolls people with ALS and related disorders, as well as healthy volunteers, to track biological markers (biomarkers) in urine, blood, and spinal fluid. The goal is to better understand how these markers change over time, which could help design more effective future …

This study looks at whether a blood test measuring a protein called neurofilament light (sNfL) can help doctors predict and manage disease activity in people with relapsing multiple sclerosis (MS). About 489 adults with MS in Germany will be observed for 24 months. The goal is to…

This study uses a special PET scan to look at tau protein buildup in the brains of African Americans who are either cognitively normal or have dementia. Researchers hope to learn how these brain changes differ across racial groups. The study involves 240 participants and uses a t…

This observational study is creating a large database of up to 96,000 people with multiple sclerosis and related conditions in Italy. Researchers will collect information on patient demographics, treatments, and disease progression over time. The goal is to better understand thes…

This study uses special brain scans (MRS) to measure two natural chemicals, GABA and glutathione, in people with Friedreich's Ataxia (FRDA). Researchers want to see if these chemicals can serve as reliable markers of the disease and how they change after taking the drug Omaveloxo…

This study tests a new radioactive compound called F 18 T807 that lights up tau tangles in the brain during a PET scan. Researchers want to see if the amount of tau relates to memory and thinking problems in people with a rare, inherited form of Alzheimer's disease. About 130 adu…

This study uses a radioactive tracer called [18F]MK-6240 to take detailed pictures of tau protein clumps in the brain, a hallmark of Alzheimer's disease. Researchers will scan 200 people from families with a rare genetic form of Alzheimer's to see how tau buildup changes over tim…

This study observes over 1,100 pregnant women with multiple sclerosis to see if taking the drug diroximel fumarate (VUMERITY) affects their babies' health. Researchers will compare birth defects, miscarriages, preterm births, and stillbirths among women who took DRF, other MS dru…

This long-term study looks at children and adults with inherited nerve and muscle disorders that start early in life, like muscular dystrophy. Researchers will track symptoms over time and collect genetic samples from affected individuals, their family members, and healthy volunt…

This study planned to see if mindfulness meditation using virtual reality could help people with ALS feel better emotionally and improve their quality of life. It was designed for adults with ALS who speak French. However, the study was withdrawn before enrolling any participants…

This study tests a new imaging method to see if white blood cells enter the brain in people with multiple sclerosis, fibromyalgia, or chronic fatigue syndrome. Participants receive their own white blood cells tagged with a radioactive tracer, then undergo a brain PET/MRI scan. Th…

This study is trying to find ways to diagnose chronic traumatic encephalopathy (CTE) in living people. Right now, CTE can only be confirmed after death. Researchers will study 350 former college and professional football players, using memory tests and other biomarkers. The goal …

This study aimed to compare T cell populations between people with multiple sclerosis and healthy controls to better understand which immune cells attack the nerves. It was withdrawn before enrolling any participants, so no results are available. The goal was to learn more about …

This study will collect and analyze genetic data from 1000 people with suspected inherited metabolic diseases, including conditions like epilepsy and mitochondrial disorders. Researchers at Karolinska University Hospital aim to improve diagnosis by using advanced genetic testing …

This study follows 640 adults with normal cognition, mild cognitive impairment, or Alzheimer's disease to track brain changes over time. Researchers use advanced brain scans and genetic tests to understand how Alzheimer's develops. The goal is to find better ways to diagnose and …

This observational study follows 367 adults with relapsing multiple sclerosis who are taking cladribine tablets (Mavenclad) in routine care. Researchers want to find out which patient characteristics predict how long people stay on the drug and how well it works. The goal is to h…

This study uses special PET/CT scans to measure inflammation in the brains of people with Alzheimer's disease or Lewy body dementia. Researchers want to see if brain inflammation is linked to memory decline and other dementia symptoms. The study also tests a new radioactive trace…

This study looks at whether diabetes or blood sugar problems can worsen thinking and memory issues in people with myotonic dystrophy type 1. Researchers will use MRI brain scans and thinking tests over 4 years to track changes. The goal is to understand why some patients have mor…

This study looks at whether improving sleep through cognitive behavioral therapy (CBT-I) can reduce neuropsychiatric symptoms like anxiety, depression, and agitation in 150 older adults with mild cognitive impairment or early Alzheimer's. Participants are randomly assigned to CBT…

This study looks at whether adults aged 65 and older with memory concerns can collect a small blood sample at home to check for Alzheimer's disease risk. Participants will use a simple device to draw blood, mail it to a lab, and get results from a doctor over video. The goal is t…

This Stanford study is testing whether non-intrusive sensors placed in the home can automatically track neuropsychiatric symptoms like mood changes and agitation in older adults. Researchers will enroll 25 participants with or at risk of mild cognitive impairment or dementia, alo…

This study looks at whether the immune system mistakenly makes antibodies that attack the body's own nerves and muscles in people with multiple sclerosis, myasthenia gravis, and similar conditions. Researchers will collect blood samples (and sometimes cheek swabs) from 120 adults…

This study follows 440 people with relapsing-remitting multiple sclerosis for 5 to 10 years after their diagnosis. Researchers will use brain scans, lab tests, and genetic information to find patterns that predict how the disease will progress. The goal is to help doctors and pat…

This study is testing two new digital tools to monitor how multiple sclerosis (MS) progresses over time. One tool uses cameras to measure movement and balance, while the other uses eye scans to detect nerve damage. Ten people with stable MS will try these tools, and the results w…

This study enrolls 500 adults with a sleep condition called REM sleep behavior disorder (RBD), which often leads to Parkinson's disease or related brain disorders. Researchers will track symptoms like thinking, movement, and smell to develop a rating scale. The goal is to prepare…

This study looks back at the medical records of 150 people diagnosed with Creutzfeldt-Jakob disease (CJD), a rare and fast-moving brain disorder. Researchers will examine symptoms, blood tests, spinal fluid, brain scans, and EEG results to find patterns that could help doctors di…

This study looks at how thinking, memory, and movement change in older adults with conditions like dementia or Parkinson's disease. Researchers will use tests, brain scans, and lab samples to find clues for earlier diagnosis and better care. About 260 people, including healthy vo…

This study looks at how certain genes influence the activity of immune cells in the brain, called microglia, in people with Alzheimer's disease. Researchers will use a special PET scan to measure these cells in about 107 older adults, some with mild memory problems or Alzheimer's…

This study tracks about 400 people with multiple sclerosis (MS) to see how many develop antibodies against the drug natalizumab when it is given as a shot under the skin. Researchers will also look at side effects and relapse rates in those who develop antibodies. The goal is to …

This study is testing a new way to analyze MRI brain scans, called Cortical Disarray Measurement (CDM), to see if it can help diagnose Alzheimer's disease more accurately. Researchers will follow 400 people with mild memory or thinking problems over time, comparing CDM results wi…

This pilot study uses special MRI scans to check if the brain's waste-clearing system, called the glymphatic system, is not working properly in people with Clinically Isolated Syndrome (CIS), which is often the first sign of Multiple Sclerosis (MS). Researchers will compare scans…

This study tests three new imaging agents (18F-RO948, 18F-MK6240, and 18F-GTP1) to see how well they detect tau protein buildup in the brains of people with Alzheimer's disease compared to healthy older adults. About 38 participants aged 50-100 will receive PET scans to compare t…

This study was designed to see if a smartphone app called iBlink can measure how well the brain learns new movements in people with spinocerebellar ataxia, a rare and serious movement disorder. Researchers planned to compare aerobic exercise with balance training to see which bet…

This study tests whether advanced MRI techniques can measure brain changes in people with ALS (Lou Gehrig's disease). Researchers will scan 119 participants three times over 8 months to see if these scans can track the disease and help diagnose it earlier. The goal is to create b…

This study looks back at the medical records of 800 people who were hospitalized with dangerously low sodium levels (≤110 mmol/L). Researchers want to learn how often serious brain complications like swelling or nerve damage occur, and how treatment affects these risks. No new tr…

This study uses advanced MRI scans and genetic tests to track how neurodegenerative diseases like frontotemporal dementia and ALS spread across the brain's network. Researchers will follow 645 participants, including patients, family members, and healthy controls, for up to 2 yea…

This study looks at 40 people with early-stage Huntington's disease and healthy volunteers to see how well two types of brain scans can detect changes over 2 years. Participants get PET and MRI scans plus clinical exams at the start and after 2 years. The goal is to find better w…

This study looks at how swallowing difficulties in people with multiple sclerosis (MS) relate to their nutrition and muscle function. Researchers will assess 34 ambulatory MS patients using questionnaires and physical tests. The goal is to better understand these connections to i…

This study checks whether a French version of a scale called PLSFRS works well for people with primary lateral sclerosis (PLS), a rare nerve disease. Researchers will ask 80 patients to fill out the questionnaire during routine check-ups every 3 to 6 months. The goal is to see if…

This study looks at a small part of the brain called the locus coeruleus, which may be one of the first areas damaged in Alzheimer's disease. Researchers will use brain scans, eye tracking, and a mild nerve stimulation device to measure how this area affects attention and memory …

This observational study follows 37 children and young adults with juvenile-onset Huntington's disease (JoHD) to understand how their brains develop differently from adult-onset cases. Participants undergo cognitive tests, behavioral assessments, and MRI scans over time. The goal…

This study is testing whether a new type of MRI can detect changes in the brain that lead to memory and thinking problems in people with multiple sclerosis (MS). Researchers will scan 75 adults with MS and give them thinking and memory tests. The goal is to see if the new MRI mea…

This study looks at whether obesity makes multiple sclerosis (MS) worse in children. Researchers will compare brain scans and blood markers between normal-weight and overweight/obese kids recently diagnosed with MS. The goal is to understand how obesity might drive inflammation a…

This study follows 302 adults with multiple sclerosis in France who are starting the drug ofatumumab as part of their normal care. Researchers will measure how patients' quality of life changes after 12 months using a special questionnaire. The goal is to understand real-world be…

This study looks at how things like social support, income, and health habits are linked to mental health and brain diseases such as depression, Alzheimer's, and Parkinson's. Researchers will collect surveys, blood samples, and optional brain scans from over 1,300 adults in Europ…

This study follows 100 people aged 60-85 with mild memory or movement problems to see if losing smell, hearing, or balance speeds up cognitive decline. Researchers will test these senses and track thinking skills and quality of life for 5 years. The goal is to understand which se…

This study was designed to test whether scheduled video calls with a nurse could help family members who make medical decisions for hospitalized older adults with Alzheimer's or similar cognitive issues. The goal was to improve communication and reduce anxiety and depression. How…

This study tested two teaching methods for nursing students: a 360-degree video experience about the brain and multiple sclerosis (MS), and a standard slideshow with the same information. About 50 students from three nursing schools took part. Researchers measured how much they l…

This study follows 200 people with Parkinson's disease or multiple sclerosis over one year to see how active they are. Participants use a smartphone app called Datos Health to track steps, workouts, and heart rate. A physical therapist sets personalized exercise goals. The goal i…

This study is creating a simple test to check if people with Alzheimer's or similar conditions can understand and agree to medical decisions. Researchers will work with 100-150 participants to compare the new test with existing methods and look at brain scans and blood markers. T…

This study tests a lifestyle program for African American men who have finished prostate cancer treatment and their spouses or partners. The goal is to see if the program can improve quality of life, diet, physical activity, and partner support. Only 6 participants were enrolled,…

This study uses special PET scans to look for signs of inflammation in the brains of people with Alzheimer's disease or mild cognitive impairment, compared to healthy volunteers. Nine participants will receive an investigational radioactive tracer called [18F]NOS, and some may al…

This study looks at how multiple sclerosis (MS) symptoms, like fatigue and thinking skills, change during different phases of the menstrual cycle. About 300 females with MS who still have periods will track their symptoms using a phone app for six months. The goal is to find patt…

This study explores how non-invasive brain stimulation can help understand and treat agitation in people with Alzheimer's and mixed dementia. Researchers will use transcranial magnetic stimulation (TMS) and electroencephalography (EEG) to study brain activity, and test whether tr…

This study is building an online platform called DBS MatchMaker to connect doctors around the world who treat rare movement disorders with deep brain stimulation (DBS). The goal is to help doctors share knowledge and find the best ways to treat patients. Up to 500 people of all a…

This study follows 5 people with a rare, late-onset form of TPP1 deficiency (a brain disease) to track how their symptoms change over time. Researchers will use tests like brain scans, eye exams, and movement assessments to better understand the condition. The goal is to gather i…

This study looks at how different patterns of deep brain stimulation (DBS) affect movement symptoms and brain activity in people with Parkinson's disease, essential tremor, multiple sclerosis, or dystonia. Researchers will test non-regular stimulation patterns to find ways to mak…

This study uses special brain scans (PET imaging) to measure two key proteins, amyloid and tau, in people with different forms of Alzheimer's disease. Researchers want to see how these protein levels change over one year. The study involves 60 adults with typical or atypical Alzh…

This observational study follows 36 people with neurologic conditions like traumatic brain injury, cerebral palsy, multiple sclerosis, or Alzheimer's who are already receiving intranasal MuSE stem cell or exosome therapy as part of their routine care. Researchers track safety and…

This study collects health information and test results from 317 people at high risk for pancreatic cancer, including those with cysts, genetic syndromes, or other risk factors. Researchers aim to build a database to find better ways to detect the disease early or prevent it. No …

This study is creating a registry of 452 adults with a family history of Alzheimer's or early memory problems. Researchers will track their health, blood markers, and thinking skills over time to see if personalized care plans can help prevent or treat the disease. The goal is to…

This study looks at how age-related sleep changes and sleep apnea might increase the risk of Alzheimer's disease. Researchers will use brain scans and overnight sleep tests in 158 healthy adults aged 55-75 to measure amyloid buildup and sleep patterns over two years. The goal is …

This study aimed to test whether a smartphone app could track multiple sclerosis (MS) symptoms and progression remotely. It planned to enroll adults with MS across different countries to see if digital measurements matched standard clinical tests. However, the study was withdrawn…

This pilot study tests whether liraglutide (Saxenda), a weight-loss drug, can raise levels of a brain-protective protein called BDNF in 30 people with multiple sclerosis, long-COVID, or leukemia who are overweight and have memory or concentration problems. Participants will injec…

This study aims to create more sensitive cognitive tests for Huntington's disease by combining brain imaging (PET and MRI) with blood markers. Researchers will study 90 participants—healthy controls, pre-symptomatic gene carriers, and early-stage patients—to understand how brain …

This observational study measures how common malnutrition is in people with relapsing-remitting multiple sclerosis (RRMS) and whether it is linked to disability. Researchers will assess nutritional status, body composition, and other factors like depression and incontinence in 16…

This study will examine lymph nodes from 5 people with relapsing-remitting multiple sclerosis who are starting ocrelizumab treatment. The goal is to see how effectively the drug removes B cells from lymph nodes, since these cells are known to be important in MS but are not well s…

This study was designed to test a wearable sensor system that tracks how people walk on different surfaces like grass, pavement, and stairs. It aimed to include healthy volunteers and people with conditions such as Parkinson's disease, dementia, stroke, multiple sclerosis, or low…

This study from Mayo Clinic is creating a large collection of blood, urine, stool, spinal fluid, and skin samples from 1000 people with ataxia and related genetic diseases, plus their healthy family members. The goal is to better understand the genetic and physical features of th…

This study tests a smart insole and phone app that track walking patterns in people with multiple sclerosis (MS). The goal is to see if this wearable device can reliably detect changes in a person's condition during daily life. 90 adults with MS will use the device at home for 6 …

This study looks at how natural hormone changes during the menstrual cycle impact brain-to-muscle communication, learning new motor skills, and fatigue in women with multiple sclerosis. Researchers will measure these factors at different cycle phases in 14 participants. The goal …

This study looks at people with early ALS who still have some unaffected body areas. Researchers want to find the very first signs of the disease spreading. By observing 100 participants over time, they hope to learn how ALS starts and progresses, which could help with earlier di…

This study looks at data from 1 million adults worldwide to see if eating nuts is linked to a lower risk of diseases like diabetes, heart disease, cancer, and dementia. Researchers will combine information from many past studies to get clearer answers. The goal is to understand i…

This study follows 135 people with Lewy body dementia over up to 5 years, using special PET scans to measure brain changes linked to memory and thinking decline. Researchers hope to find imaging markers that show how the disease progresses. Participants will have regular tests an…

This observational study will enroll 100,000 people over age 45 to track early signs of Alzheimer's and Parkinson's using smartphone-based tests, genetic data, and brain scans. Researchers aim to develop better ways to identify who is at risk before symptoms worsen. Participants …

This study looks at how the body's automatic nervous system controls blood flow in abdominal veins and how that might lead to high blood pressure in people with Multiple System Atrophy (MSA). Researchers will measure vein responses in about 16 participants aged 40-80 who have MSA…

This study aims to find a combination of markers—from genetics, immune system, and brain scans—that are linked to how severe multiple sclerosis (MS) becomes. Researchers will follow 120 people with MS and their siblings who also have the condition. Participants undergo neurologic…

The ALOHA study is a community-based research project for adults aged 50 and older in the Washington, D.C., Maryland, and Virginia area. Over five years, participants receive annual health assessments—including physical and cognitive tests—and get a personalized 'Health Passport'…

This study tests whether smartphone-based challenges and surveys can reliably measure multiple sclerosis (MS) progression. Researchers will compare these digital biomarkers with standard clinical exams, brain scans, and lab tests in 300 people with MS over two years. The goal is …

This study looks at what happens when healthy older adults learn their personal five-year risk of developing Alzheimer's dementia. Researchers are giving 450 participants their risk estimates at different times and tracking changes in mood, thinking, and distress. The goal is to …

This study looks at whether the Timed Up and Go (TUG) test, a common walking test, can reliably measure how people with multiple sclerosis (MS) perform when they have to walk and think at the same time. Fifty volunteers with MS will do the TUG test alone, while counting backwards…

This study uses a portable 48-hour EEG monitor to check for hidden seizures in people with early-onset Alzheimer's disease (ages 40-64). Researchers want to learn how common seizures and epilepsy are in this group. The study involves 20 participants and is purely observational, m…

This study brings together patient registries from 10 countries to analyze data from 700 people with spinal and bulbar muscular atrophy (SBMA). Researchers will look at changes in muscle function, walking ability, and age of symptom onset. The goal is to better understand how the…

This study looks at whether carvedilol, a drug used for heart failure, can reverse early heart changes seen in people with a sleep disorder that puts them at high risk for Parkinson's disease. Fifteen participants with REM sleep behavior disorder or reduced sense of smell will ta…

This study looks at whether terazosin, a drug used for high blood pressure, can change heart nerve activity in people at high risk for Parkinson's disease. Researchers are studying 15 adults with REM sleep behavior disorder (a strong early sign of Parkinson's) to see if the drug …

This study aims to test a risk assessment screening and a caregiver coaching program to prevent elder abuse in people with dementia. Researchers will compare caregivers who receive the screening and coaching to those who do not, looking at stress, depression, and anxiety. The goa…

This study looks at whether combining a special breathing technique (called acute intermittent hypoxia, or AIH) with mild electrical stimulation of leg muscles can boost brain-to-muscle signals in people with relapsing forms of multiple sclerosis. About 40 participants will have …

This long-term study uses yearly brain scans, genetic tests, and thinking/memory assessments to track changes in nearly 1,800 people with various dementias (like Alzheimer's and vascular dementia) and over 140 healthy older adults. The goal is to better diagnose, monitor, and eve…

This study is testing a new, low-cost eye scanner to see if it can take clear pictures of the retina, the light-sensitive layer at the back of the eye. Researchers will compare images from this device with those from a standard, expensive scanner. They will also measure the thick…

This study was designed to see if a tracking system called Care Companion could help family caregivers of people with dementia who are at risk of wandering. The study was withdrawn before any participants were enrolled, so no results are available. It would have asked caregivers …

This study looks back at 10,000 hospital patients to learn more about low sodium levels (hyponatremia). Researchers want to know how common it is, how fast doctors correct it, and whether that affects patient outcomes like brain damage or death. No new drug or treatment is being …

This study is analyzing blood samples from 1,799 people with Alzheimer's, dementia, depression, bipolar disorder, schizophrenia, or Parkinson's disease. Researchers want to see if certain substances in the blood can help doctors diagnose and manage these conditions more accuratel…

This study is a registry that collects information from about 2,000 people with mild cognitive impairment or Alzheimer's disease. Researchers will track how the disease progresses and how treatments work in real-world settings. The goal is to better understand Alzheimer's and imp…

This study looks at balance and movement problems in people with stroke, Parkinson's disease, or multiple sclerosis. Researchers will use special devices to measure how well participants can keep their balance and walk. The goal is to learn more about these issues so that rehabil…

This study tests whether a phone app called StudyU can help people with heart failure reach their recommended beta blocker dose. Five adults aged 65 and older with heart failure will use the app to track their medication. The goal is to see if the app is practical and acceptable …

This study is a registry that will follow about 1,000 adults with multiple sclerosis (MS) who are starting a new MS medication. Researchers will collect information on side effects, relapses, and daily function over time to compare how well different treatments work in real life.…

This study uses small body-worn sensors to measure movement during simple coordination tests in people with spinocerebellar ataxia, a condition that affects balance and walking. Researchers aim to see if these sensors can accurately track disease severity and progression. The stu…

This study aimed to see if an online lesson could improve people's knowledge and healthy habits for preventing dementia. It planned to enroll Canadians aged 16 and older without dementia, giving some the prevention lesson and others a different topic. However, the study was withd…

This study follows 66 people with primary progressive multiple sclerosis (PPMS) and healthy volunteers for two years to understand how thinking and memory change over time. Participants take cognitive tests and undergo MRI scans to see how brain tissue damage relates to mental de…

This study compares virtual (telehealth) care to standard in-person visits for 120 adults recently diagnosed with multiple sclerosis. The goal is to see if virtual care can prevent disability progression just as well, while also being more convenient and cost-effective. Participa…

This study will test whether it's possible to create a registry for people with Alzheimer's who are receiving lecanemab infusions, along with their care partners. Researchers want to see if they can collect information on quality of life and caregiver burden in a real-world clini…